News
Fusion Antibodies present their ‘world class, groundbreaking expertise and services’
In this interview with our CEO, Dr Richard Jones talks about our significant contract announcement with a key US Biotech company, and the organisation’s growth strategy over the next 24 months, focusing on three key pillars:
1. Commercial excellence
2. Providing cutting edge services to not only meet, but exceed clients expectations
3. Sustained investment in R&D to ensure innovation remains at the forefront of the organisation